Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CVS HEALTH CorpCVS · Entity 2884 | EVP - Transformation | December 02, 2020 | December 04, 2020 |
| Ontrak, Inc.OTRK · Entity 78207 | Chief Executive Officer | April 20, 2022 | April 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CVS HEALTH Corp
Report date December 02, 2020 · Filed December 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,855 |
Reported balance
After 2020-12-02 transaction · row 1
1 source rowRow 1 · 2020-12-02 · Tax withholding · Disposed 926 · Balance 6,855 F1: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards. |
| Common Stock (restricted)SEC Table I · non-derivative | Direct | 7,543 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,543 |
| CVS Health Future Fund 401(k) Common StockSEC Table I · non-derivative | Direct | 505 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 505 |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $37.91 · Expires 2026-02-18 | Direct | 6,634 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,634 F2: SARs became exercisable on 2/19/2019. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $45.91 · Expires 2027-02-16 | Direct | 11,333 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 11,333 F3: SARs became exercisable in two equal annual installments beginning on 2/17/2019. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $52.42 · Expires 2027-05-09 | Direct | 3,067 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,067 F4: SARs became exercisable in two equal annual installments beginning on 5/10/2019. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $54.19 · Expires 2029-04-01 | Direct | 44,037 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 44,037 F5: Options became exercisable in four equal annual installments, commencing 4/1/2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $58.34 · Expires 2030-04-01 | Direct | 28,159 |
Reported balance
Holding disclosure · report date 2020-12-02 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 28,159 F6: The number of shares subject to the option were calculated using a 30-day average price. F7: Option becomes exercisable in four equal annual installments, commencing 4/1/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards.
F2: SARs became exercisable on 2/19/2019.
F3: SARs became exercisable in two equal annual installments beginning on 2/17/2019.
F4: SARs became exercisable in two equal annual installments beginning on 5/10/2019.
F5: Options became exercisable in four equal annual installments, commencing 4/1/2020.
F6: The number of shares subject to the option were calculated using a 30-day average price.
F7: Option becomes exercisable in four equal annual installments, commencing 4/1/2021.
Ontrak, Inc.
Report date April 20, 2022 · Filed April 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2031-04-12 | Direct | 400,000 |
Reported balance
After 2022-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-20 · Grant · Acquired 400,000 · Balance 400,000 F2: The reporting person agreed to the repricing of an option granted to him on April 12, 2021. F1: 133,334 of these shares vested on April 12, 2022 and the remaining shares vest equally over the following 24 months, such that all shares shall be vested on April 12, 2024. There was no change to the vesting schedule in connection with the repricing transaction on April 20, 2022. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.22 · Expires 2031-04-12 | Direct | 0 |
Reported balance
After 2022-04-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-20 · Disposition to issuer · Disposed 400,000 · Balance 0 F2: The reporting person agreed to the repricing of an option granted to him on April 12, 2021. F1: 133,334 of these shares vested on April 12, 2022 and the remaining shares vest equally over the following 24 months, such that all shares shall be vested on April 12, 2024. There was no change to the vesting schedule in connection with the repricing transaction on April 20, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 133,334 of these shares vested on April 12, 2022 and the remaining shares vest equally over the following 24 months, such that all shares shall be vested on April 12, 2024. There was no change to the vesting schedule in connection with the repricing transaction on April 20, 2022.
F2: The reporting person agreed to the repricing of an option granted to him on April 12, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2022 Filed Apr 22, 2022 16:46 UTC | Ontrak, Inc. OTRK · Entity 78207 | Disposition to issuerOption (right to buy) · Derivative | 400,000 | Not disclosed Strike: $31.22 | Not disclosed |
DisclosureSEC source: 0001437749-22-009545 · rdgdoc.xml · derivative · entry 2 Mayhew Jonathan E. · CIK 0001806604 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ontrak, Inc. Common Stock · 400,000 shares Expires 2031-04-12 F2 · price: The reporting person agreed to the repricing of an option granted to him on April 12, 2021. F1 · derivative.exercise_date: 133,334 of these shares vested on April 12, 2022 and the remaining shares vest equally over the following 24 months, such that all shares shall be vested on April 12, 2024. There was no change to the vesting schedule in connection with the repricing transaction on April 20, 2022. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 16:46 UTC | Ontrak, Inc. OTRK · Entity 78207 | GrantOption (right to buy) · Derivative | 400,000 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001437749-22-009545 · rdgdoc.xml · derivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Ontrak, Inc. Common Stock · 400,000 shares Expires 2031-04-12 F2 · price: The reporting person agreed to the repricing of an option granted to him on April 12, 2021. F1 · derivative.exercise_date: 133,334 of these shares vested on April 12, 2022 and the remaining shares vest equally over the following 24 months, such that all shares shall be vested on April 12, 2024. There was no change to the vesting schedule in connection with the repricing transaction on April 20, 2022. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 17:26 UTC | Ontrak, Inc. OTRK · Entity 78207 | GrantOption (right to buy) · Derivative | 74,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001593968-22-000865 · primary_01.xml · derivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Ontrak, Inc. Common Stock · 74,000 shares Expires 2029-04-12 F1 · kind: These securities were granted to Mr. Mayhew for his services as the Chief Executive Officer of the Company. F2 · derivative.exercise_date: 25% of these options shall vest one year from the date of grant and the remaining options shall vest in 12 equal quarterly installments thereafter over the next three years. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:18 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 926 | $69.63 | $64,477.38 |
DisclosureSEC source: 0001127602-20-030563 · form4.xml · nonDerivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · EVP - Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,855 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of restricted stock awards. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:56 UTC | CVS HEALTH Corp CVS · Entity 2884 | SaleCommon Stock | 10,556 | $65.00 | $686,140.00 |
DisclosureSEC source: 0001127602-20-018061 · form4.xml · nonDerivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · EVP - Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,732 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:36 UTC | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 28,159 | $58.61 Strike: $58.61 | $1,650,398.99 |
DisclosureSEC source: 0001127602-20-013237 · form4.xml · derivative · entry 4 Mayhew Jonathan E. · CIK 0001806604 · EVP, Chief Transformation Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,159 Underlying: Common Stock · 28,159 shares Expires 2030-04-01 F2 · derivative.exercise_price: The number of shares subject to the option were calculated using a 30-day average price. F3 · derivative.exercise_date: Option becomes exercisable in four equal annual installments, commencing 4/1/2021. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:36 UTC | CVS HEALTH Corp CVS · Entity 2884 | Tax withholdingCommon Stock | 763 | $58.34 | $44,513.42 |
DisclosureSEC source: 0001127602-20-013237 · form4.xml · nonDerivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · EVP, Chief Transformation Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,288 F1 · shares: Surrender of shares in payment of withholding taxes due upon the vesting of a restricted stock award. Read SEC document |
| April 01, 2020 Filed Apr 7, 2020 21:42 UTC Amendment | CVS HEALTH Corp CVS · Entity 2884 | GrantStock Option · Derivative | 28,159 | $0.00 Strike: $58.34 | $0.00 |
DisclosureSEC source: 0001127602-20-013415 · form4a.xml · derivative · entry 1 Mayhew Jonathan E. · CIK 0001806604 · EVP, Chief Transformation Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,159 Underlying: Common Stock · 28,159 shares Expires 2030-04-01 F1 · derivative.exercise_price: This Form 4/A is being filed in order to correct the exercise price (Table II, column 2) for the stock option granted on 4/1/2020, which was reported incorrectly on the original Form 4 due to a clerical error. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.